Previous 10 | Next 10 |
Marinus Pharmaceuticals, Inc. (MRNS) Q1 2022 Earnings Conference Call May 12, 2022, 04:00 PM ET Company Participants Sasha Damouni Ellis - VP, Corporate Communications, and IR Scott Braunstein - Chief Executive Officer Joe Hulihan - Chief Medical Officer Steve Pfanstiel - Chief Financial Offi...
Marinus Pharmaceuticals press release (NASDAQ:MRNS): Q1 GAAP EPS of -$0.52 beats by $0.33. Revenue of $14.19M (+684.0% Y/Y) beats by $11.91M. For further details see: Marinus Pharmaceuticals GAAP EPS of -$0.52 beats by $0.33, revenue of $14.19M beats by $11.91M
ZTALMY ® (ganaxolone) U.S. commercial launch on track for July 2022 Phase 3 RAISE trial in refractory status epilepticus continues to advance with resumption of screening and recruitment; data readout expected second half 2023 Site activations advance in Phase 3 Trust...
AAIC, ACB, ACHV, AFRM, AGRO, AGRX, APDN, APTX, AQN, AVPT, AXU, BANX, BBI, BEAT, BIOL, BLBD, BLND, BOXL, BSQR, CBAY, CDXC, CLLS, CLVR, CODX, COMP, CORZ, CRMD, CTIC, CURI, CWCO, DARE, DUOL, EDR, ETON, EYEN, FIGS, GPL, GWH, HLI, HTGM, IBIO, IDN, OTCQB:IGXT, IMMR, INDI, INTZ, INUV, JOBY, KMPH, LC...
Today, we put biopharma concern Marinus Pharmaceuticals back in the spotlight for the first time in more than a year. Despite the fall in the stock recently, analyst firms remain strongly positive on the shares. An updated investment analysis follows in the paragraphs below. ...
Marinus Pharmaceuticals (NASDAQ:MRNS) said it had resumed screening and recruitment for its phase 3 RAISE trial in refractory status epilepticus (RSE), a condition characterized by prolonged or repetitive seizures despite treatment with benzodiazepines and one antiepileptic drug. The company ...
Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has resumed screening and recruitment for the Phase 3 RAISE (Randomized Therapy in Status Epilepticus) ...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the first quarter ended March 31, 2022 after the market closes on...
Results demonstrate safety and efficacy of ZTALMY, first FDA-approved treatment for seizures associated with CDKL5 deficiency disorder in patients two years and older Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of in...
Marinus Pharmaceuticals (NASDAQ:MRNS) said it received $30M in funding under an existing Oaktree Capital Management credit agreement. The company said the additional funding became available as a result of the U.S. Food and Drug Administration’s recent approval of the company’s&...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will h...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schall Law Firm PR Newswire LOS ANGELES , July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing ...
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...